Loading organizations...
Nebula Genomics is a technology company.
I am unable to fulfill this request. I encountered persistent '429 Too Many Requests' errors when attempting to fetch content from nebula.org and its Wikipedia page. This prevents me from gathering the necessary in-depth information from official, full-page sources, which is a core requirement of the prompt ("Prefer evidence from fetched full-page content over snippets").
Furthermore, initial web search snippets suggest that Nebula Genomics might be shutting down or is no longer operational, as indicated by a Reddit post. Without being able to access the official website or a comprehensive, current source, I cannot confirm the company's present status, which is crucial for writing a profile in the requested present tense and with a forward-looking vision.
Therefore, I cannot confidently write a thorough, accurate, and properly sourced company profile that adheres to all specified constraints.
Nebula Genomics has raised $8.3M across 2 funding rounds.
Nebula Genomics has raised $8.3M in total across 2 funding rounds.
Nebula Genomics has raised $8.3M in total across 2 funding rounds.
Nebula Genomics's investors include Dawn Capital, Goodwater Capital, Mathias Schilling, LAUNCH, Xfund, Dmitry Dakhnovsky, Eric Feng, Patrick S. Chung, Tony Jamous, Robert Nelsen, Fenbushi Capital, F-Prime Capital.
Nebula Genomics is a personal genomics company that provides affordable whole genome sequencing (WGS) services, enabling consumers to access their complete genetic data securely.[1][2][3] It serves individuals worldwide seeking health insights, ancestry analysis, and personalized reports, while addressing genetic privacy concerns through blockchain and privacy-preserving tech; the company solves the high cost and data control issues in direct-to-consumer (DTC) genetic testing by offering 30x WGS for $299 via partnerships like BGI.[2][6] Founded in 2018 and acquired by ProPhase Labs in 2021, Nebula built growth through product launches like its 2020 30x sequencing kit and alliances with firms such as EMD Serono and Oasis Labs, creating diverse genomic datasets for research and drug discovery.[3][6]
Nebula Genomics was founded in 2018 by Professor George Church, a pioneering geneticist at Harvard known as the "Founding Father of Genomics," who co-invented CRISPR-Cas9, advanced next-generation sequencing (NGS), and initiated the Personal Genome Project.[1][2][4] Church, who has started over 20 companies, launched Nebula to democratize personal genomics, drawing from his lab's breakthroughs in DNA sequencing and gene editing to make WGS accessible globally.[1][4] Early traction came from investor backing by Khosla Ventures, F-Prime Capital, and others, plus a 2019 alliance with EMD Serono for data sharing and the 2020 BGI partnership for affordable sequencing, culminating in its 2021 acquisition by ProPhase Labs.[2][3][6]
Nebula rides the genomics revolution, where falling sequencing costs and tools like CRISPR enable personalized healthcare, shifting from reactive to predictive medicine.[1][4] Its timing aligns with post-Human Genome Project scalability, addressing DTC market privacy scandals that stalled growth while creating massive datasets for AI-driven drug discovery amid pharma's need for diverse human genetics data.[2][6] Market forces like BGI's high-throughput tech and rising demand for ancestry/health insights favor it, influencing the ecosystem by pioneering user-owned data marketplaces that empower consumers, researchers, and biopharma.[3][7]
Post-2021 acquisition by ProPhase Labs, Nebula is positioned to scale WGS integration into clinical and consumer health under a public company structure, potentially expanding free sequencing incentives and pharma partnerships.[3][7] Trends like AI-genomics fusion, large-scale genome engineering (e.g., Church's Genome Project-Write), and global data diversity will shape it, evolving its influence toward enabling curative gene therapies and de-extinction tech while upholding privacy.[1][4] As genomics remakes healthcare from destiny to blueprint, Nebula exemplifies how founder-driven innovation accelerates this shift.[1]
Nebula Genomics has raised $8.3M across 2 funding rounds. Most recently, it raised $4.0M Series A in October 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2018 | $4.0M Series A | Dawn Capital, Goodwater Capital, Mathias Schilling, LAUNCH, Xfund, Dmitry Dakhnovsky, Eric Feng, Patrick S. Chung, Tony Jamous | |
| Aug 29, 2018 | $4.3M Seed | Robert Nelsen, Fenbushi Capital, F-Prime Capital, GreatPoint Ventures, Heartbeat Labs, Hemi Ventures, Hikma Ventures, Khosla Ventures, Tim Chang, Mirae Asset, Windham Venture Partners |